| Drug Name |
Dabrafenib mesylate |
| Drug ID |
BADD_D00567 |
| Description |
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013 for the treatment of melanoma [L2718].
In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2714]. |
| Indications and Usage |
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. |
| Marketing Status |
Not Available |
| ATC Code |
L01EC02 |
| DrugBank ID |
DB08912
|
| KEGG ID |
D10104
|
| MeSH ID |
C561627
|
| PubChem ID |
44516822
|
| TTD Drug ID |
D05ROI
|
| NDC Product Code |
81719-015; 54893-0052; 81719-016 |
| Synonyms |
dabrafenib | GSK 2118436 | GSK2118436 | GSK-2118436 |
